The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
TIGER 1: A randomized, open-label, phase 2/3 study of rociletinib (CO-1686) or erlotinib as first-line treatment for EGFR-mutant non-small cell lung cancer (NSCLC).
 
D. Ross Camidge
Honoraria - Clovis Oncology
Consulting or Advisory Role - Clovis Oncology
 
Juergen Wolf
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; MSD; Novartis; Pfizer; Roche Pharma AG
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; MSD; Novartis; Pfizer; Roche Pharma AG
Research Funding - Bayer (Inst); Boehringer Ingelheim (Inst); Novartis (Inst); Pfizer (Inst); Roche Pharma AG (Inst)
 
Jason B. Litten
Employment - Clovis Oncology
 
Linda A Higashi
Employment - Clovis Oncology
 
Jeffrey D. Isaacson
Employment - Clovis Oncology
 
Tony Mok
Employment - The Chinese University of Hong Kong
Honoraria - Amgen; AstraZeneca; AVEO; Biomarin; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Eisai; Janssen; Lilly; Merck Serono; Novartis; Pfizer; Roche/Genentech; Taiho Pharmaceutical
Consulting or Advisory Role - Amgen; AstraZeneca; AVEO; Biomarin; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Eisai; Janssen; Lilly; Merck Serono; Novartis; Pfizer; Roche/Genentech; Taiho Pharmaceutical
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; Lilly; Merck Serono; Pfizer; Roche
Research Funding - AstraZeneca
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Boehringer Ingelheim; Lilly; Merck Serono; Pfizer; Roche